The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

“The applications of lentiviral vectors are diverse,” she says, pointing out that while 65% of the CDMO’s customers are developing immunotherapies, like CAR-Ts, TCRs, NK-CARs, NK-TCRs, TILs ...

GAITHERSBURG, Md., May 2, 2025 /PRNewswire/ -- Vector BioMed (VBM), a leading lentiviral vector CDMO advancing access to gene therapies, will showcase its innovations at two major industry events ...

In this GEN webinar, our expert panelists will discuss how they aim to develop technologies to improve Lentiviral vector yields and scalability. Specifically, we will hear about the challenges ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

Download this application note to receive step-by-step guidance about optimizing and standardizing scalable lentiviral vector production and clarification. Sponsored by. Top Image Credit: ©iStock, ...

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia LONDON & NEW YORK, April ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies.. The latest entry into the CDMO viral vector ...

Discover how innovative production and clarification products improve lentiviral vector generation. Share. The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, ...

ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer Provided by Business Wire Apr 17, 2025, 6:00:00 AM ...

UCL leveraged ViroCell's expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ("ViroCell" ...

Lentigen’s lentiviral gene therapy assets were acquired by German company Miltenyi Biotec in 2014. “Now is the perfect time to launch our business,” Dropulić said in a prepared statement.